In the first quarter of 2017, pharmaceutical deals dropped even further, compared with the previous quarter, and the same quarter the year before.
After a booming January, February deal volume dies.
Perrigo finally sold its royalty interest in Tysabri, a multiple sclerosis drug that it acquired as part of Elan Corporation back in 2013. Royalty Pharma, the hostile bidder for Elan back then, paid $2.2 billion for Tysabri royalties.
The pharmaceutical industry has been the behemoth of healthcare M&A, usually accounting for the largest dollar amounts spent in any given year and often one of the most active in terms of number of transactions.
The days of mega-mergers in the pharmaceutical sector aren’t necessarily over, but those deals will be fewer and farther between, going forward. Nearly 60 deals have been announced in 2016 through the middle of May, and just 17 have an entire company as the target. The largest, so far, is Shire‘s (NASDAQ: SHPG) $32 billion […]